Favorable July 12 Safety Monitoring Committee Meeting for Nymox Pharmaceutical Pivotal Phase 3 NX-1207 Trials

HASBROUCK HEIGHTS, N.J., July 17, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company’s Phase 3 pivotal trials for NX-1207, Nymox’s investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 12, 2012 was favorable and indicated no significant safety concerns for the two pivotal U.S. trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are nearing completion at over 70 well-known urology investigative sites throughout the U.S.